Brought to you by 
Abbott gets rights to Reata's Phase II bardoxolone; Reata reacquires rights
24 Feb 2023
Executive Summary
Reata Pharmaceuticals Inc. (developing oral anti-inflammatories) has licensed Abbott Laboratories Inc. exclusive rights outside the US and some Asian countries to develop and commercialize bardoxolone (RTA402), which is in late Phase II trials for chronic kidney disease (CKD).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott gets rights to Reata's Phase II bardoxolone; Reata reacquires rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice